Whoops.
The novel antithrombotic vorapaxar causes intracranial hemorrhage in patients with a history of stroke, Merck announced, explaining why stroke survivors were dropped from trials of the experimental drug.

Whoops.
The novel antithrombotic vorapaxar causes intracranial hemorrhage in patients with a history of stroke, Merck announced, explaining why stroke survivors were dropped from trials of the experimental drug.
